Hospitalization Patterns of Diabetic Patients: A Six Year Experience at King Khalid University Hospital

Al-Maatouq, Mohamed A.

doi:10.5144/0256-4947.1994.486

Cited by 2 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few health economic analyses have been conducted in the Middle East. Patients with diabetes account for 2.6% of all hospital admissions and 3.5% of all hospital stays in Saudi Arabia (18). A report from a health insurance company in Abu Dhabi, reported in the press, claimed recently that the cost of managing diabetes in the UAE will reach Dh 10 billion (US $2.7 billion) by 2020 (19).…”

Section: Introductionmentioning

confidence: 99%

Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin

Al-Maatouq

Alarouj

Assaad

et al. 2009

International Journal of Clinical Practice

View full text Add to dashboard Cite

Aims:Increases in the prevalence of type 2 diabetes will likely be greater in the Middle East and other developing countries than in most other regions during the coming two decades, placing a heavy burden on regional healthcare resources.Methodology:Medline search, examination of data from major epidemiological studies in the Middle Eastern countries.Results:The aetiology and pathophysiology of diabetes appears comparable in Middle Eastern and other populations. Lifestyle intervention is key to the management of diabetes in all type 2 diabetes patients, who should be encouraged strongly to diet and exercise. The options for pharmacologic therapy in the management of diabetes have increased recently, particularly the number of potential antidiabetic combinations. Metformin appears to be used less frequently to initiate antidiabetic therapy in the Middle East than in other countries. Available clinical evidence, supported by current guidelines, strongly favours the initiation of antidiabetic therapy with metformin in Middle Eastern type 2 diabetes patients, where no contraindications exist. This is due to its equivalent or greater efficacy relative to other oral antidiabetic treatments, its proven tolerability and safety profiles, its weight neutrality, the lack of clinically significant hypoglycaemia, the demonstration of cardiovascular protection for metformin relative to diet in the UK Prospective Diabetes Study and in observational studies, and its low cost. Additional treatments should be added to metformin and lifestyle intervention as diabetes progresses, until patients are receiving an intensive insulin regimen with or without additional oral agents.Conclusions:The current evidence base strongly favours the initiation of antidiabetic therapy with metformin, where no contraindications exist. However, metformin may be under-prescribed in the Middle East.

show abstract

Section: Introductionmentioning

confidence: 99%

Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin

Al-Maatouq

Alarouj

Assaad

et al. 2009

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Among the 25 studies reporting type 2 or total diabetes and which presented data on CVD and at least one other category of admission, CVD was the leading cause in 19/25 (76%) articles [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] (Tables 2 and 3; Figure S1). Among the 19 papers reporting subtypes of CVD, ischaemic or coronary heart disease was the leading cause of diabetes admission in 11 papers 13,14,19,[23][24][25][27][28][29][30][31] and heart failure was the leading cause in eight papers.…”

Section: Reasons For Admission In People With Total or Type 2 Diabetesmentioning

confidence: 99%

“…Among the 19 papers reporting subtypes of CVD, ischaemic or coronary heart disease was the leading cause of diabetes admission in 11 papers 13,14,19,[23][24][25][27][28][29][30][31] and heart failure was the leading cause in eight papers. [8][9][10][11]15,26,32,33 When examining the reporting of admissions over time, CVD was the leading cause of admission in 9/10 (90%) papers published from 1980 to 2014, 8,9,11,13,14,17,18,20,24 and in 10/15 (67%) papers published from 2015 onwards (Figures S2 and S3). 10,12,15,16,19,[21][22][23]25,26 CVD was the leading cause of admission in 18/21 (86%) studies in high-income countries but in only 1/4 (25%) studies in upper-middle-income countries (Supplementary Figures S4 and S5).…”

Section: Reasons For Admission In People With Total or Type 2 Diabetesmentioning

confidence: 99%

“…[29][30][31][32]36 A significant number of papers (n = 22) reported admission for renal conditions in a consistent manner. Among these, renal conditions were the first, second and third-leading cause of admission in 1/22 (5%), 37 4/22 (18%) 14,17,18,25 and 4/22 (18%) of studies 13,20,21,32 respectively.…”

Section: Reasons For Admission In People With Total or Type 2 Diabetesmentioning

confidence: 99%

“…11,12,19,33 Cancer of the digestive system was the leading cause of cancer admission among people with diabetes 38,39 (Supplementary Table S1). Diseases of the digestive system were the second-leading cause of admission in 1/20 (5%) of the studies, 35 the third-leading cause of hospitalisation in 2/20 (10%) of the studies 17,22 and the fourth-leading cause of admission in 3/20 (15%) of the studies. 8,9,16 Injury and poisoning were the third-leading cause of admission in 1/22 (5%) of the studies, 31 the fourth-leading cause of admission in 1/22 (6%) of the studies 22 and the fifth-leading cause of admission in 4/22 (18%) of the studies.…”

Section: Reasons For Admission In People With Total or Type 2 Diabetesmentioning

confidence: 99%

See 2 more Smart Citations

Hospital admissions among people with diabetes: A systematic review

Feleke,

Sacre,

Tomic

et al. 2023

Diabet Med

View full text Add to dashboard Cite

ObjectiveTo describe the reasons for hospital admission among people with diabetes.MethodsWe searched Emcare, Embase, Medline, and Google Scholar databases for population‐based studies describing the causes of hospitalisation among people with diabetes. We included articles published in English from 1980 to 2022. For each study, we determined the most frequent reasons for admission. Studies were assessed for quality using the Newcastle Ottawa quality assessment tool.Results6920 research articles were retrieved from the search of all sources. After screening the titles and abstracts of these, we reviewed the full text of 135 papers and finally included data from 42 studies. Admissions among the total diabetes were reported in 25 papers: five articles reported type 1 diabetes alone, 10 articles reported type 2 diabetes alone, and the remaining two articles reported type 1 and type 2 diabetes separately. Among the 25 total and type 2 diabetes studies that reported the distribution of hospitalisations in broad categories, cardiovascular diseases (CVD) were the leading cause of admission in 19/25 (76%) of studies. Among the 19 studies that reported CVD admissions by subcategories, ischaemic or coronary heart disease was the leading subtype of CVD in 58% of studies. The other common causes of admissions were infections, renal disorders, endocrine, nutritional, metabolic and immunity disorders. In people with type 1 diabetes, acute diabetes complications were the leading cause of admission.ConclusionCVD are the leading cause of hospital admission for people with diabetes, with ischaemic or coronary heart disease as the predominant subtype.

show abstract

Hospitalization Patterns of Diabetic Patients: A Six Year Experience at King Khalid University Hospital

Cited by 2 publications

References 13 publications

Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin

Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin

Hospital admissions among people with diabetes: A systematic review

Contact Info

Product

Resources

About